**Core Concept:**
Autonomic neuropathy is a complication of diabetes that affects the autonomic nervous system, leading to dysfunction in various organs and systems, such as cardiovascular, gastrointestinal, and genitourinary systems. Early morning hypotension is a common manifestation of autonomic neuropathy in diabetics, which is associated with supine hypertension, orthostatic hypotension, and dizziness on standing.

**Why the Correct Answer is Right:**
In this scenario, the patient presents with symptoms like dizziness and hypotension upon waking up in the morning. Option D, Midodrine, is a selective alpha-1 receptor agonist that helps in raising blood pressure by constricting blood vessels and increasing cardiac output. This is an appropriate treatment option for orthostatic hypotension, which is a significant feature of autonomic neuropathy-induced hypotension.

**Why Each Wrong Option is Incorrect:**
A. Option A (Fludrocortisone) is a mineralocorticoid hormone that increases aldosterone levels, causing sodium retention and water loss, which would be counterproductive for treating hypotension.
B. Option B (Fludrocortisone) is also a mineralocorticoid hormone, and similar to option A, it would not effectively treat the autonomic dysfunction-induced hypotension in diabetic patients.
C. Option C (Fludrocortisone) is another mineralocorticoid hormone that would not target the autonomic dysfunction causing hypotension in diabetic patients.

**Clinical Pearl:**
Autonomic neuropathy-induced hypotension in diabetics requires a drug that enhances sympathetic activity to counteract the decreased baroreceptor reflex sensitivity. Midodrine is a selective alpha-1 receptor agonist that addresses this issue, making it the correct answer. However, mineralocorticoid hormones like fludrocortisone are not tailored for this specific issue and would not effectively treat the hypotension caused by autonomic dysfunction in diabetics.